Last reviewed 2026-04-22 · How we verify

AV7909

AV7909 is an anthrax vaccine that stimulates immune responses against anthrax toxins through a combination of protective antigen and adjuvant components.

AV7909 is an anthrax vaccine that stimulates immune responses against anthrax toxins through a combination of protective antigen and adjuvant components. Used for Prophylaxis of anthrax infection in at-risk populations, Post-exposure prophylaxis following anthrax exposure.

At a glance

Mechanism of action

AV7909 is an improved formulation of anthrax vaccine adsorbed (AVA) that combines recombinant protective antigen with a novel adjuvant to enhance immunogenicity and reduce the number of doses required for protection. The vaccine works by priming both humoral and cellular immune responses against anthrax protective antigen, enabling the immune system to neutralize anthrax toxins and prevent infection.

Approved indications

• Prophylaxis of anthrax infection in at-risk populations
• Post-exposure prophylaxis following anthrax exposure

Common side effects

• Injection site reactions (erythema, induration, pain)
• Myalgia
• Fatigue
• Headache

Key clinical trials

• Anthrax AV7909 Boost Evaluation Study (PHASE2)
• Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study (PHASE2)
• Anthrax AV7909 Liquid vs Lyophilized (PHASE1)
• VELOCITY: An Anthrax Vaccine Clinical Study (PHASE3)
• Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults (PHASE1)
• A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels (PHASE2)
• BARDA Securing Anthrax Immunity For the Elderly (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.